← Leaderboards
Carl Atkinson
University Of Florida
$8,241,342
Attributed
$12,673,932
Total exposure
9
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.7M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,673,932 · 9
By mechanism
R01$8,310,696 · 5
U01$3,576,949 · 2
R56$786,287 · 2
Top collaborators
- Stephen Tomlinson8 shared
- Jennifer Konopa Mulligan5 shared
- Andrew Robert Judge4 shared
- Jason R. Mccarthy4 shared
- Michael J Yost1 shared
Most similar at University Of Florida
Same institution · by research overlap
- Gilbert Rivers Upchurch$11,289,054
- Andrew Robert Judge$8,002,138
- Zhihua Jiang$3,629,047
- Kate Suzanne Carroll$13,212,881
- Jon Dobson$575,046
Others in their field
Top investigators on “Inflammation”
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
- Sharon L Hillier · Magee-Women'S Hospital Of Upmc$89,523,713
- David Heimbrook · Leidos Biomedical Research, Inc.$85,243,263
- Randall J Bateman · Washington University$64,707,456
- Peter Scott Heeger · Case Western Reserve University$56,547,884
Research focus
InflammationComplementComplement InactivatorsComplement ActivationCellsComplement SystemClinically RelevantImmuneResponsePlayLinkMediatingT-LymphocyteInjuryEventComplement PathwayProteinsChronicInflammatoryFunctional DisorderPathogenesisTissuesInhibitor/AntagonistPathway Interactions
Grant awards (32)
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis$452,090
R01 · FY2025 · AI
The Complement System and Cancer Cachexia$439,073
R01 · FY2025 · AR
Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantation$434,685
U01 · FY2025 · AI · contact PI
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis$469,935
R01 · FY2024 · AI
The Complement System and Cancer Cachexia$462,810
R01 · FY2024 · AR
Targeted delivery of immunosuppressive agents to the graft endothelium forthe prevention of rejection in lung transplantation$449,683
U01 · FY2024 · AI · contact PI
The Complement System and Cancer Cachexia$477,124
R01 · FY2023 · AR
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis$458,537
R01 · FY2023 · AI · contact PI
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation$405,353
U01 · FY2023 · AI · contact PI
The Complement System and Cancer Cachexia$477,124
R01 · FY2022 · AR
Targeted delivery of immunosuppressive agents to the graft endothelium for the prevention of rejection in lung transplantation$418,478
U01 · FY2022 · AI · contact PI
Complement driven innate and adaptive autoreactivity in lung transplantation$444,968
R01 · FY2021 · HL · contact PI
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis$433,451
R01 · FY2021 · AI · contact PI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2021 · AI
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery$337,831
R56 · FY2021 · AI · contact PI
Brain death associated vascularized composite allograft injury and its impact on alloimmunity and functional recovery$74,706
R56 · FY2021 · AI · contact PI
Complement driven innate and adaptive autoreactivity in lung transplantation$451,162
R01 · FY2020 · HL · contact PI
Epithelial cell complement production in the pathogenesis of chronic rhinosinusitis$425,970
R01 · FY2020 · AI · contact PI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2020 · AI
Complement driven innate and adaptive autoreactivity in lung transplantation$144,877
R01 · FY2020 · HL · contact PI
Complement driven innate and adaptive autoreactivity in lung transplantation$476,475
R01 · FY2019 · HL · contact PI
Cell survival in engineered skeletal muscle: The role of complement$405,831
R01 · FY2019 · EB
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2019 · AI
Complement driven innate and adaptive autoreactivity in lung transplantation$483,405
R01 · FY2018 · HL · contact PI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2018 · AI
Graft-targeted anti-complement therapy to reduce cardiac graft injury and allograft vasculopathy$373,750
U01 · FY2017 · AI
Immune sensing of ischemic injury and complement-dependent modulation of alloimmunity in cardiac transplantation$373,750
R56 · FY2015 · AI
The Role of Complement in the Pathogenesis of Emphysema$357,761
R01 · FY2014 · HL · contact PI
The Role of Complement in the Pathogenesis of Emphysema$347,540
R01 · FY2013 · HL · contact PI
The Role of Complement in the Pathogenesis of Emphysema$365,063
R01 · FY2012 · HL · contact PI
The Role of Complement in the Pathogenesis of Emphysema$368,750
R01 · FY2011 · HL · contact PI
The Role of Complement in the Pathogenesis of Emphysema$368,750
R01 · FY2010 · HL · contact PI